Ribavirin has shown an inhibitory activity over several molecular targets implicated in the development of hematological and solid tumors (e.g., EZH2, IMPDH, MYC) [32, 33, 34]; the activity over AKT/mTORC1 and MEK/ERK pathways, in addition to the inhibitory effect on cell growth (Fig. 5C), support its utility as a promising option for treatment of tumors, including cervical cancer. This evidence concerns the gene AKT1 and cervical carcinoma.